The China National Medical Products Administration has approved Gilead Sciences’ (NASDAQ:GILD) Vosevi (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) for the once-daily treatment of chronic hepatitis C virus (HCV) infection in adults without cirrhosis or with compensated cirrhosis who have failed prior treatment with direct-acting antiviral therapy.
There are ~10M Chinese with HCV infection.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.